Lung cancer remains one of the leading causes of cancer-related deaths worldwide. At ImmunityBio, we are advancing clinical research to explore new treatment options that harness the immune system. Our goal is to help expand possibilities for patients facing this disease. Learn more about our research: https://lnkd.in/gjHm-nak
ImmunityBio, Inc.
Biotechnology Research
San Diego, CA 26,304 followers
Outsmart Your Disease™
About us
ImmunityBio, Inc. (formerly NantKwest, Inc.) is developing cell and immunotherapy products that are designed to help strengthen each patient’s natural immune system, potentially enabling it to outsmart the disease and eliminate cancerous or infected cells. The activation of the innate immune system is key to the development of immunological memory. Over the last two decades, our founder and Executive Chairman Dr. Patrick Soon-Shiong has investigated mechanisms to activate the immune system to attack tumors that can otherwise evade and escape the body’s defense mechanisms. After inventing the world’s first protein nanoparticle drug, Abraxane, Dr. Soon-Shiong turned his focus to the next generation of immunotherapies. ImmunityBio was founded in 2014 to create innovative immunotherapies that address serious unmet needs in oncology and infectious diseases. "At ImmunityBio, we envision a day when we no longer fear cancer but are able to conquer it, thanks to the biological wonder that is the human immune system. Our scientists are working to develop remarkable new therapies that harness that inherent power by amplifying both branches of the immune system, attacking cancerous or infected cells today while building immunological memory for tomorrow. The goal: to reprogram the patient’s immune system and treat the host rather than just the disease." -Dr. Patrick Soon-Shiong, Executive Chairman
- Website
-
https://www.ImmunityBio.com
External link for ImmunityBio, Inc.
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- San Diego, CA
- Type
- Public Company
- Specialties
- Immunotherapy, Cancer, Infectious Diseases, Natural Killer, T Cell, Vaccines, Oncology, Vaccine, Fusion Proteins, Clinical Trials, Manufacturing, COVID-19, Yeast, and Cell Therapy
Locations
Employees at ImmunityBio, Inc.
Updates
-
With high rates of recurrence and the risk of advancing disease, non-muscle invasive bladder cancer (NMIBC) remains a significant burden for both patients and healthcare providers. ImmunityBio is working to meet this challenge through the development of innovative treatment approached aimed at addressing the disease more effectively. Learn more: https://lnkd.in/gJmy4pZg
-
We’ve announced new paradigm-changing findings from the Phase 2 QUILT-3.055 study, demonstrating ANKTIVA® (nogapendekin alfa inbakicept-pmln) reverses lymphopenia (low natural killer and T cells) in patients with checkpoint inhibitor-resistant advanced non-small cell lung cancer (NSCLC), with this reversal resulting in significant prolonged median overall survival (mOS). Read more: https://lnkd.in/gks_pXYF
-
ImmunityBio, Inc. reposted this
He calls himself a “billionaire by accident.” Dr. Patrick Soon-Shiong - surgeon turned inventor who never stopped caring for patients. And if he could describe himself in one sentence? “I wish I could have been Kobe Bryant.” Exclusive CancerWorld cover story by Gevorg Tamamyan 👇 🔗 https://lnkd.in/eGQKNXcK OncoDaily Los Angeles Times ImmunityBio, Inc. NantHealth NantWorks OncoDaily IO #oncology #oncodaily #nantworks #immunitybio #immunotherapy #cancerresearch #cancer #latimes
-
-
September marks Ovarian Cancer Awareness Month; a time to highlight the importance of early detection and ongoing research in the fight against this disease. Our team is always striving to push the boundaries of what is possible in ovarian cancer treatment. This month, and every month, we're dedicated to supporting patients and driving research forward. Learn more about our trial: https://lnkd.in/g4VquVHD
-
-
We're focused on innovating beyond standard treatments so that we can give the body the tools it needs to lead its own fight against cancer. Learn more about our pipeline: https://lnkd.in/dYwrAigj
-
-
We’ve announced that our initial data shows 100% disease control in 5 out of 5 patients with recurrent glioblastoma after being treated with our ANKTIVA, NK cell therapy plus the Optune Gio® device. Read more: https://lnkd.in/gasXc28V
-
We've announced our new study, called COVID-4.019-Long, which further expands our clinical research efforts to assess ANKTIVA’s potential beyond cancer or cancer-related diseases. Learn more about the study and its potential impact: https://lnkd.in/gdMdQFbE
-
We announced early results from our QUILT-106 Phase I trial showing complete responses in the first two late-stage Non-Hodgkin Waldenström lymphoma patients treated with our CD19 CAR-NK cell therapy. Learn more: https://lnkd.in/gjp5sc6Y
-
ImmunityBio, Inc. reposted this
Our robust pipeline of clinical trials is all about turning insights into better outcomes for people facing a wide range of cancers. The ImmunityBio team remains committed to transforming research into tangible impact in the lives of patients. Explore our latest trials: https://lnkd.in/dYwrAigj
-